Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

385
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
385
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

470
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights from PSMAfore: impact on health-related quality of life.

Translational andrology and urology·2026
Same author

Quantitative SISCOM assessment for epileptogenic zone localization: insights from a multicenter study comparing two software platforms in temporal lobe epilepsy.

Frontiers in neurology·2025
Same author

Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study.

EJNMMI reports·2025
Same author

Theranostics Nuclear Medicine in Prostate Cancer.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

<sup>18</sup>F-Fluoride PET/CT-Updates.

Seminars in nuclear medicine·2024
Same author

68 Ga-DOTATATE PET/CT Versus 18 F-FDG PET/CT in TENIS Syndrome: A Head-to-Head Comparison With Elevated and Suppressed TSH Levels in Papillary Thyroid Carcinoma-A Pilot Study.

Clinical nuclear medicine·2024

Related Experiment Video

Updated: Jan 8, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

Assessing therapeutic response to Radium-223.

Caroline Torricelli1, Ludmila Almeida2, Elba Etchebehere3

  • 1University of Campinas, Campinas, Brazil.

Seminars in Nuclear Medicine
|December 18, 2025
PubMed
Summary

Evaluating radium-223 (223Ra) treatment response in metastatic castration-resistant prostate cancer (mCRPC) requires a multimodal approach. Combining biomarkers and advanced imaging improves therapeutic assessment and patient outcomes.

Keywords:
Metastatic castration-resistant prostate cancerMolecular imagingPersonalized treatmentRadium-223Response biomarkersTargeted alpha therapy

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Biomarker Discovery

Background:

  • Radium-223 (223Ra) is an alpha-emitting radiopharmaceutical improving overall survival (OS) and reducing skeletal-related events (SREs) in metastatic castration-resistant prostate cancer (mCRPC).
  • Assessing 223Ra therapeutic response is challenging due to its unique mechanism affecting bone remodeling and the tumor microenvironment.
  • Conventional serum tumor biomarkers (e.g., PSA, ALP) are insufficient for comprehensive response evaluation.

Purpose of the Study:

  • To review and integrate current and emerging strategies for evaluating 223Ra treatment response in mCRPC.
  • To highlight the necessity of a multimodal approach combining various assessment tools beyond traditional biomarkers.

Main Methods:

  • Review of classic serum biomarkers (PSA, ALP) for prognostic and monitoring roles.
  • Examination of emerging liquid biopsy tools: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), bone metabolism markers, and exosomes.
  • Exploration of imaging biomarkers: 18F-fluoride PET/CT, whole-body diffusion-weighted MRI, PSMA PET/CT, and RECIST criteria.
  • Inclusion of innovative technologies: radiomics and artificial intelligence (AI) for data integration and outcome prediction.

Main Results:

  • Classic biomarkers offer prognostic and monitoring insights but are limited in comprehensively assessing 223Ra response.
  • Liquid biopsy tools show potential in reflecting metabolic changes induced by 223Ra therapy.
  • Imaging biomarkers are central to response assessment, with ongoing advancements and limitations.
  • Radiomics and AI can integrate diverse data (clinical, molecular, imaging) to enhance outcome prediction and personalize care.

Conclusions:

  • A multimodal strategy integrating biological markers (serum, liquid biopsy) and advanced imaging is crucial for accurate 223Ra response evaluation.
  • Innovative analytical methods like radiomics and AI can significantly improve outcome prediction and treatment personalization.
  • Enhanced response assessment through a multimodal approach is expected to lead to improved clinical outcomes for mCRPC patients treated with 223Ra.